Zacks Investment Research upgraded shares of FURIEX PHARMACT (FURX) from UNDERPERFORM to NEUTRAL on October 24, 2012, with a target price of $18.70.
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. It partners with pharmaceutical and biotechnology companies and has a diversified product portfolio and pipeline with multiple therapeutic candidates including late-stage assets and a product on the market. Its product pipeline includes Priligy Alogliptin Nesina Alogliptin/Actos Combination Alogliptin/Metformin Combination Fluoroquinolone Mu Delta and PPD 10558. Furiex Pharmaceuticals, Inc. is based in Morrisville, North Carolina.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on FURIEX PHARMACT (FURX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment